Cognition and amyloid load in Alzheimer disease imaged with florbetapir F 18 (AV-45) positron emission tomography

American Journal of Geriatric Psychiatry

Volumn 21, Issue 3, 2013, Pages 272-278

  Rosenberg, Paul B ^a   Wong, D F ^a,b   Edell, S L ^c   Ross, J S ^d   Joshi, A D ^e   Brasic J R ^b   Zhou, Y ^b   Raymont, V ^b   Kumar, A ^b   Ravert, H T ^b   Dannals, R F ^b   Pontecorvo, M J ^e   Skovronsky, D M ^e,f   Lyketsos, C G ^a  

^a JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c Community Health Research ^*  (United States)

^d Memory Enhancement Center   (United States)

^e AVID RADIOPHARMACEUTICALS   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

18 flourine; Alzheimer; Amyloid; Cognition; PET tracer; Positron emission tomography; Standardized uptake value ratios

Indexed keywords

AMYLOID; FLORBETAPIR F 18;

AGED; ALZHEIMER DISEASE; ALZHEIMERS DISEASE ASSESSMENT SCALE COGNITIVE SUBSCALE; AMNESIA; ANTERIOR CINGULATE; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; COGNITION; CONTROLLED STUDY; CORRELATIONAL STUDY; CROSS-SECTIONAL STUDY; DRUG UPTAKE; EPISODIC MEMORY; FEMALE; FOLLOW UP; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; OCCIPITAL CORTEX; PARIETAL CORTEX; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PRECUNEUS; PSYCHOLOGIC ASSESSMENT; TASK PERFORMANCE; TEMPORAL CORTEX; VERBAL CATEGORY FLUENCY; WECHSLER LOGICAL MEMORY IA;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID; ANILINE COMPOUNDS; BIOLOGICAL MARKERS; BRAIN; CASE-CONTROL STUDIES; COGNITION; COGNITION DISORDERS; ETHYLENE GLYCOLS; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY;

EID: 84875449522     PISSN: 10647481     EISSN: 15457214     Source Type: Journal    
DOI: 10.1016/j.jagp.2012.11.016     Document Type: Article

References (22)

1. Klunk WE, Engler H, Nordberg A, et al: Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55:306-319
2. Okello A, Koivunen J, Edison P, et al: Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology 2009; 73:754-760
3. Choi SR, Golding G, Zhuang Z, et al: Preclinical properties of 18FAV-45: a PET agent for Abeta plaques in the brain. J Nucl Med 2009; 50:1887-1894
4. Wong DF, Rosenberg PB, Zhou Y, et al: In Vivo imaging of amyloid deposition in Alzheimer's disease using the Radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med 2010; 51: 913-920
5. Pike KE, Savage G, Villemagne VL, et al: Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007; 130:2837-2844
6. Rentz DM, Locascio JJ, Becker JA, et al: Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol 2010; 67: 353-364
7. Alzheimer's Association: Research consent for cognitively impaired adults: recommendations for institutional review boards and investigators. Alzheimer Dis Assoc Disord 2004; 18:171-175
8. McKhann G, Drachman D, Folstein M, et al: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944
9. Folstein MF, Folstein SE, McHugh PR: "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198
10. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141:1356-1364
11. Wechsler D: Manual for the Wechsler Memory Scale-Revised. San Antonio, TX, The Psychological Corporation, 1987
12. Hulette CM, Welsh-Bohmer KA, Murray MG, et al: Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol 1998; 57:1168-1174
13. Price JL, Morris JC: Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 1999; 45: 358-368
14. Mintun MA, Larossa GN, Sheline YI, et al: [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006; 67:446-452
15. Jagust WJ, Bandy D, Chen K, et al: The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement 2010; 6:221-229
16. Mormino EC, Kluth JT, Madison CM, et al: Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 2009; 132:1310-1323
17. Resnick SM, Sojkova J, Zhou Y, et al: Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology 2010; 74:807-815
18. Storandt M, Mintun MA, Head D, et al: Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch Neurol 2009; 66:1476-1481
19. Jack CR Jr, Lowe VJ, Weigand SD, et al: Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009; 132:1355-1365
20. Grimmer T, Henriksen G, Wester HJ, et al: Clinical severity of Alzheimer's disease is associated with PIB uptake in PET. Neurobiol Aging 2009; 30:1902-1909
21. Chetelat G, Villemagne VL, Bourgeat P, et al: Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol 2010; 67:317-324
22. Reitz C, Honig L, Vonsattel JP, et al: Memory performance is related to amyloid and tau pathology in the hippocampus. J Neurol Neurosurg Psychiatry 2009; 80:715-721